{'fraction_non_alphanumeric': 0.019637462235649546, 'fraction_numerical': 0.0015105740181268882, 'mean_word_length': 4.867256637168142, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Identification of blood eQTLs for AD risk loci

Alzheimer’s disease (AD) is the sixth leading cause of death in the US and most common form of dementia, affecting an estimated 5 million individuals. Currently there are no publicly available treatments for clinical or pre‐clinical symptoms of AD as well as there is high number of genetic variants involved in the onset and progression of the disease. The Alzheimer’s disease Neuroimaging Initiative (ADNI) aims to determine imaging, clinical and genetic biomarkers for early detection and treatment of AD. The goal of this study was to identify blood eQTLs for the genes located under the GWAS loci for AD risk.